- Home
- AES vs HALO Comparison
AES vs HALO Comparison
Compare AES & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- HALO
- Stock Information
- Founded
- AES 1981
- HALO 1998
- Country
- AES United States
- HALO United States
- Employees
- AES N/A
- HALO N/A
- Industry
- AES Electric Utilities: Central
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AES Utilities
- HALO Health Care
- Exchange
- AES Nasdaq
- HALO Nasdaq
- Market Cap
- AES 7.1B
- HALO 7.3B
- IPO Year
- AES 1991
- HALO N/A
- Fundamental
- Price
- AES $10.58
- HALO $57.75
- Analyst Decision
- AES Buy
- HALO Buy
- Analyst Count
- AES 11
- HALO 9
- Target Price
- AES $20.40
- HALO $62.78
- AVG Volume (30 Days)
- AES 15.0M
- HALO 1.1M
- Earning Date
- AES 02-27-2025
- HALO 02-18-2025
- Dividend Yield
- AES 6.65%
- HALO N/A
- EPS Growth
- AES N/A
- HALO 63.33
- EPS
- AES 1.44
- HALO 3.43
- Revenue
- AES $12,284,000,000.00
- HALO $1,015,324,000.00
- Revenue This Year
- AES $0.37
- HALO $23.48
- Revenue Next Year
- AES $3.69
- HALO $18.16
- P/E Ratio
- AES $7.37
- HALO $16.84
- Revenue Growth
- AES N/A
- HALO 22.44
- 52 Week Low
- AES $9.88
- HALO $37.73
- 52 Week High
- AES $22.21
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- AES 42.84
- HALO 62.93
- Support Level
- AES $9.88
- HALO $56.07
- Resistance Level
- AES $10.91
- HALO $60.67
- Average True Range (ATR)
- AES 0.36
- HALO 1.43
- MACD
- AES 0.08
- HALO -0.22
- Stochastic Oscillator
- AES 66.13
- HALO 48.86
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.